… Safety analysis showed that immunotherapy was well-tolerated. All … in patients received
vaccines. In conclusion, immunotherapy is a promising treatment for advanced NSCLC patients. …

… “wildtype” NSCLC as a control group in the meta-analysis is … this meta-analysis were
heterogeneous including NSCLC with … In both ROS1+ NSCLC studies by Ng and colleagues and …

… In patients with NSCLC, the findings of the meta-analysis indicate that antibiotic use
before or during treatment with ICI leads to a median OS decreased by more than 6 months. …

… patients with lung cancer without treatment has not been performed. We conducted a systematic
review and meta-analysis of the natural history of patients … enrolled patients with NSCLC…

… In the present meta-analysis, whose advantage over previous publications lies in higher …
both OS and PFS in TKI-treated NSCLC patients. Our results therefore suggest the possibility …

… patients excluded from the investigators' original analyses, and reinstated in this meta-analysis,
data for two other patients … Therefore, this meta-analysis is based on data from 15 trials20…

… with locally advanced non-small cell lung cancer (NSCLC), it is not clear whether the …
Patients and methods This meta-analysis was based on individual patient data from published and …

… The aim of this meta-analysis is to combine and analyse simultaneously all randomized trials
comparing platinum-based doublets and single-agent therapy in NSCLC and PS2 patients. …

… sample sizes with limited statistical power, it is necessary to assess the possible
association between PD-L1 and the prognosis for NSCLC patients using an up-to-date meta-analysis. …

… Findings In this meta-analysis of 43 studies involving 5431 patients with resectable NSCLC,
… ; I2 = 0%) but not overall survival for patients with baseline tumor PD-L1 levels less than 1% …